A new study presented at the Endocrine Society's annual meeting (ENDO 2026) reveals that adults with obesity who lost weight using GLP-1 medications, such as Ozempic or Wegovy, significantly reduced their physical activity. The research, the first of its kind, analyzed data from 753 participants in a National Institutes of Health program, linking their medical records with fitness tracker activity.
Key Findings
The study found that the average number of steps per day decreased from 5,047 to 4,487, while moderate-to-vigorous physical activity fell from 28 to 22 minutes daily. The largest declines were observed in men and those with joint or muscle pain. Other factors like age, heart failure, or prior stroke did not significantly alter the results.
Expert Insights
Study lead Sajana Maharjan, MD, of HSHS St. John's Hospital, emphasized that GLP-1 drugs reduce both fat and lean muscle mass, making physical activity essential for preserving strength and long-term health. Obesity medicine specialist Dr. Rocio Salas-Whalen recommended body composition testing to determine the suitability of GLP-1 medications.
Broader Context
The findings challenge the assumption that weight loss through medication would lead to increased physical activity. The study highlights the importance of exercise for individuals using GLP-1 medications to maintain muscle mass and overall health.